Compounds > ciprofloxacin-7-ethylenediamine
Page last updated: 2024-12-06

ciprofloxacin-7-ethylenediamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ciprofloxacin-7-ethylenediamine: metabolite of ciprofloxacin; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID63000
CHEMBL ID1086529
SCHEMBL ID3975715
MeSH IDM0152812

Synonyms (29)

Synonym
7-(2-aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid
ciprofloxacin-7-ethylenediamine
7-(2-aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
CHEMBL1086529
7-[(2-aminoethyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
103222-12-4
y7a089aj9y ,
7-ethylenediamine ciprofloxacin
desethylene-ciprofloxacin
3-quinolinecarboxylic acid, 7-((2-aminoethyl)amino)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
unii-y7a089aj9y
desethylene ciprofloxacin
7-aea-ciprofloxcin
7-(2-aminoethylamino)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
bay-r-3964
m1-ciprofloxacin
enrofloxacin for veterinary use impurity g [ep impurity]
7-((2-aminoethyl)amino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ciprofloxacin metabolite 1
ciprofloxacin impurity c [ep impurity]
desethyleneciprofloxacin
enrofloxacin impurity g
SCHEMBL3975715
DTXSID80145701
STL483383
7-(2-aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (ethylenediamine compound)
Q27294345
7-[(2-aminoethyl)amino]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
PD061131

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters for ciprofloxacin were not significantly altered in cirrhotic patients."( The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989)		0.28

Dosage Studied

ExcerptRelevanceReference
" Therefore it appears from this study that no dosage adjustment is required in patients with hepatic cirrhosis."( The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID483697Antimicrobial activity against Haemophilus influenzae ATCC 492472010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID1459109Antibacterial activity against erythromycin susceptible Streptococcus pneumoniae by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID483691Antimicrobial activity against macrolide-sensitive Staphylococcus aureus ATCC 137092010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID1459108Antibacterial activity against constitutively macrolide/lincosamide/streptogramin B-resistant Streptococcus pneumoniae by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID483699Antimicrobial activity against inducible macrolide and constitutive lincosamide, streptogramin-resistant Streptococcus pneumoniae 58 Spain2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID483701Antimicrobial activity against macrolide-sensitive Staphylococcus aureus PK12010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID1459111Antibacterial activity against constitutively macrolide/lincosamide/streptogramin B-resistant Staphylococcus aureus by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID1459110Antibacterial activity against inducibly macrolide/lincosamide/streptogramin B-resistant Staphylococcus aureus by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID1459113Antibacterial activity against Mef-mediated macrolide efflux resistant Streptococcus pneumoniae by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID1459116Antibacterial activity against Haemophilus influenzae by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID1459112Antibacterial activity against erythromycin susceptible Streptococcus pyogenes by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID483700Antimicrobial activity against inducible macrolide and constitutive lincosamide, streptogramin-resistant Streptococcus pyogenes 166 GR-micro2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID483695Antimicrobial activity against inducible macrolide, lincosamide, streptogramin-resistant Streptococcus pyogenes Finland 112010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID1459114Antibacterial activity against erythromycin susceptible Staphylococcus aureus by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID1459115Antibacterial activity against Mef-mediated macrolide efflux resistant Streptococcus pyogenes by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
AID483698Antimicrobial activity against inducible macrolide, lincosamide, streptogramin-resistant Streptococcus pneumoniae 134 GRM2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID483702Antimicrobial activity against inducible macrolide-resistant Streptococcus pyogenes Finland 32010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID483694Antimicrobial activity against macrolide-resistant Streptococcus pneumoniae Ci1372010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.
AID1459107Antibacterial activity against constitutively macrolide/lincosamide/streptogramin B-resistant Streptococcus pyogenes by agar microdilution method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's4 (36.36)18.2507
2000's1 (9.09)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		5.08101aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
7-ethoxycoumarin
7-ethoxycoumarin : A member of the class of coumarins that is umbelliferone in which the hydroxy group at position 7 is replaced by an ethoxy group.		2.1510aromatic ether;
coumarins
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.1510macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
oxociprofloxacin
oxociprofloxacin: structure given in first source; ciprofloxacin metabolite		4.2841cyclopropanes;
N-arylpiperazine;
piperazinone;
quinolinemonocarboxylic acid;
quinolone		drug metabolite
bay-s 9435
sulfociprofloxacin: structure given in first source; ciprofloxacin metabolite. sulfociprofloxacin : An organosulfonic acid that is ciprofloxacin carrying a sulfo group at position 4 of the piperazine ring. It is a metabolite of ciprofloxacin.		4.2841cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
organosulfonic acid;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		drug metabolite;
human urinary metabolite
a 195773
[no description available]		2.1510macrolide antibiotic;
monosaccharide derivative;
quinolines		antibacterial drug;
protein synthesis inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.4920macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
hmr 3647
[no description available]		2.4920
ConditionIndicatedRelationship StrengthStudiesTrials
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		01.9810
E coli Infections
[description not available]		01.9710
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		01.9710
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9710
Cirrhosis, Liver
[description not available]		01.9710
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		01.9710